Monday, January 21, 2019
Differences in Earnings Releases and 10-Ks

Wednesday, January 16, 2019
The Importance of Textual Analysis

Tuesday, January 8, 2019
A Look at Climate Change Disclosures

Wednesday, January 2, 2019
Quants: Point-in-Time Data for Backtesting

Friday, December 28, 2018
Now Showing: Controls & Procedures

Thursday, December 27, 2018
A Reminder on Non-GAAP Reporting Rules

Monday, December 17, 2018
Researching PG&E’s Wildfire Risk

Wednesday, December 12, 2018
Tracking Brexit Disclosures

Thursday, December 6, 2018
Campbell Soup: Looking Behind the Label

Sunday, December 2, 2018
SEC Comment Letters: The Amazon Example

Wednesday, November 28, 2018
Measuring Big Pharma’s Chemical Dependency

Monday, November 26, 2018
Analysts, Can You Relate? A True Story

Monday, November 19, 2018
Digging Up Historical Trend Data: Quest Example

Sunday, November 11, 2018
Cost of Revenue, SG&A: Q3 Update

Monday, November 5, 2018
Lease Accounting: FedEx vs. UPS

Saturday, November 3, 2018
New Email Alerting Powers

Wednesday, October 31, 2018
PTC and Two Tales of Revenue

Tuesday, October 30, 2018
10-K/Q Section Text Change Detection

Sunday, October 28, 2018
Finding Purchase Price Allocation

Sunday, October 21, 2018
Charting Netflix Growth in Three Ways

Archive  |  Search:
R&D Spending on the Rise, 2013-2016
Monday, March 13, 2017

Good news for science and math majors: Corporate America is spending more to keep you busy.

Calcbench looked at reported research & development spending among the S&P 500 the other day for the years 2013 through 2016. By just about every definition, the numbers look good. R&D spending is up among the group in absolute dollars, and as a percentage of revenue. Average spending per filer is also up, both in dollar terms and as a percentage of revenue. And more companies are disclosing R&D spending within our sample of 428 companies that had filed their 2016 reports as of March 13.

In other words: yay science!

First let’s look at the bigger picture. Below is a chart of R&D spending for the whole population fo 428 filers for the last four years.

Next, let’s remember that only 170 companies in our sample reported any R&D expenditures at all in 2016; the rest didn’t. And while the number of filers reporting R&D costs has risen in the last few years, that rise actually is quite small: up from 167 filers in 2013.

In other words, all those companies reporting no R&D spending pull down the average numbers quite a lot. So let’s cut those science no-shows loose, and look at the sub-group of purists keeping it real since 11th grade chemistry class. Their numbers below. The total R&D numbers are the same (because we only stripped out the zero-dollar filers), but the averages are now much higher.

Lastly, we decided to rank 2016 filers by R&D spending as a percentage of revenue, and then R&D spending in absolute dollars—with (perhaps to little surprise) wildly different results. Here are the top 10 spenders as a percent of revenue:

Almost all are pharmacuetical companies. That’s expected; most pharmaceutical companies spend boatloads on research before they even get a drug to market and see their first dime of revenue. Once a drug does reach market, the odds of it becoming a blockbuster are still slim.

Now let’s look at the top 10 in terms of absolute dollars:

This time only three pharmaceutical companies crack the top 10 (Merck, Pfizer, and Johnson & Johnson), and naturally Google leads the whole bunch—Google being Google and all.

As more filers submit their 2016 reports in coming weeks and months, we’ll do a more in-depth analysis of R&D. For now, however, if investing in research dollars is an omen of future growth and a brighter society, the omens are pointing in the right direction.

FREE Calcbench Premium
Two Week Trial

Research Financial & Accounting Data Like Never Before. More features and try our Excel add-in. Sign up now to try the Premium Suite.